We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

276 hedge funds and large institutions have $3.04B invested in Pacira BioSciences in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 105 increasing their positions, 82 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 26

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

28% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 82

11% more capital invested

Capital invested by funds: $2.75B → $3.04B (+$298M)

7% more funds holding

Funds holding: 259 → 276 (+17)

3.11% more ownership

Funds ownership: 110.52% → 113.63% (+3.1%)

67% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $5.08M

Holders
276
Holders Change
+17
Holders Change %
+6.56%
% of All Funds
4.25%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
46
Increased
105
Reduced
82
Closed
26
Calls
$1.67M
Puts
$5.08M
Net Calls
-$3.42M
Net Calls Change
-$7.42M

Top Buyers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
+$24.6M
2
AC
Armistice Capital
New York
+$20.7M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$14.7M
4
Marshall Wace
Marshall Wace
United Kingdom
+$10.5M
5
HCM
Hodges Capital Management
Texas
+$9.26M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$20.5M
2
Wells Fargo
Wells Fargo
California
-$18M
3
NPIC
Neumeier Poma Investment Counsel
California
-$16.2M
4
Goldman Sachs
Goldman Sachs
New York
-$14.3M
5
TA
Tamarack Advisers
California
-$7.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
251
Cornerstone Advisory
Maryland
$6K +$5.51K +100 New
CFD
252
Creative Financial Designs
Indiana
$6K +$5.51K +100 New
RPCONE
253
Retirement Planning Company of New England
Rhode Island
$6K +$5.51K +100 New
LF
254
Lee Financial
Texas
$6K +$5.73K +104 New
Group One Trading
255
Group One Trading
Illinois
$5K +$4.19K +76 New
FF
256
FourThought Financial
Florida
$4K – – –
FRA
257
Front Row Advisors
California
$4K – – –
RMC
258
Resources Management Corp
Connecticut
$4K – – –
Bessemer Group
259
Bessemer Group
New Jersey
$4K +$3.86K +70 New
C
260
Covestor
United Kingdom
$4K +$3.86K +70 New
FPS
261
Fieldpoint Private Securities
Connecticut
$2K -$1.65K -30 -55%
PCG
262
Private Capital Group
Connecticut
$2K – – –
S
263
SignatureFD
Georgia
$2K – – –
SMA
264
Sage Mountain Advisors
Georgia
$2K +$2.04K +37 New
Manulife (Manufacturers Life Insurance)
265
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.35K -$20K -362 -2%
PCH
266
Polar Capital Holdings
United Kingdom
$1.04K – – –
MPWT
267
MassMutual Private Wealth & Trust
Connecticut
$1K +$607 +11 New
EWA
268
EverSource Wealth Advisors
Alabama
$1K +$1.16K +21 New
SSA
269
Schonfeld Strategic Advisors
New York
– -$6.66M -118,970 Closed
Voloridge Investment Management
270
Voloridge Investment Management
Florida
– -$4.53M -80,849 Closed
JG
271
Jefferies Group
New York
– -$1.61M -28,755 Closed
HWAM
272
Hennion & Walsh Asset Management
New Jersey
– -$1.27M -22,606 Closed
HF
273
HRT Financial
New York
– -$1.07M -19,157 Closed
JCIA
274
Jackson Creek Investment Advisors
Colorado
– -$1.03M -18,332 Closed
ICM
275
III Capital Management
Florida
– -$784K -14,000 Closed
8 9 10
11
12

PCRX Hedge Fund Activity: Q4 2021 in Review

276 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2021, worth a combined $3.04B — up 11% from $2.75B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PCRX positions and 26 closed out — a net gain of 20 holders — while 105 added to existing stakes and 82 trimmed.

The largest buyer was Paulson & Co, adding an estimated $24.6M. The largest seller was Deerfield Management, cutting an estimated $20.5M.

  • 276 institutional investors held Pacira BioSciences (PCRX) as of Q4 2021, up from 259 in Q3 2021.
  • Funds reported $3.04B of Pacira BioSciences stock for Q4 2021, up 11% quarter-over-quarter.
  • 46 funds opened new Pacira BioSciences positions in Q4 2021 and 26 closed out, a net change of +20 holders.
  • The largest Pacira BioSciences buyer in Q4 2021 was Paulson & Co, an estimated $24.6M added.
  • The largest Pacira BioSciences seller in Q4 2021 was Deerfield Management, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2021.